In The Meantime Men Executive Director Jeffrey King
Tuesday night, In The Meantime Men’s Group is holding a community dialogue on one of the most hotly contested issues in the HIV/AIDS community: “Brothers, would you take HIV medication if it prevented HIV?”
Community Dialogue @ Brothers Reaching Brothers, BRB, 4067 W. Pico Blvd., LA CA 90019, 7:00p.m., (Open, all are welcome to attend).
Here’s the issue: Biomedical Prevention Medications That Prevents HIV – A Community Discussion About Pre-exposure Prophylaxis (PrEP) Presenter: Dr. Raphael J. Landovitz, M.D., MSc.
The HIV Pre-Exposure ProphylaxisInitiative (iPrEx) was a multinational randomized controlled study of HIV pre-exposure prophylaxis (PrEP) in 2,499 HIV-negative men who have sex with men (MSM) and transgender women who have sex with men. The trial examined the efficacy of Truvada (a fixed dose combination of 2 antiretroviral medications: FTC and Tenofovir) taken every day to prevent HIV infection. The study found that participants receiving Truvada had a 44% reduction in new HIV infections compared with those who received placebo.
About the presenter:Dr. Landovitz is an UCLA Assistant Professor of Medicine in the Division of Infectious Diseases. His research interests include biomedical interventions for HIV prevention, immunology of infection acquired as breakthrough of prevention strategies, novel agents and strategies for treatment of HIV infection, and complications of antiretroviral therapy, the latter number for which I collaborate with the NIH/NIAID-sponsored AIDS Clinical Trials Group and HIV Prevention Trial Network networks. He is the Principal Investigator for the Post-exposure Prophylaxis Pilot Program, which is embedded in a publicly-funded medical outpatient services programs. Dr. Landovitz directs a series of studies examining the ways to optimize the use of biomedical prevention strategies in substance-abusing populations at high risk for HIV-infection.
Recent Comments